Dear Ms. Moyle:

Please refer to your supplemental new drug applications (sNDAs) dated and received on June 28, 2019 (NDA 022181) and July 1, 2019 (NDA 205065), and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kuvan (sapropterin dihydrochloride) tablets and Kuvan (sapropterin dihydrochloride) powder for oral solution.

The two Prior Approval supplemental new drug applications provide for updates to the Prescribing Information in accordance with the Pregnancy and Lactation Labeling Rule (PLLR) format.

We remind you that you will need to submit a labeling supplement to update the final numbers in the labeling once the PKU Maternal Phenylketonuria Observational Program (PKU MOMS) pregnancy registry is completed and the corresponding PMR is fulfilled.

APPROVAL & LABELING

We have completed our review of the applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.1 Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, Instructions for Use), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

---

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the Prescribing Information to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.

³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).

³ When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).

⁴ [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf)  
U.S. Food and Drug Administration  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)
Instructions for completing the form can be found at FDA.gov.\textsuperscript{5} For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.\textsuperscript{6}

If you have any questions, call CAPT Mimi Phan, Regulatory Project Manager, at (301) 796-5408.

Sincerely,

\{See appended electronic signature page\}

Joyce Korvick, MD, MPH
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
  - Instructions for Use

\textsuperscript{5} \url{http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf}
\textsuperscript{6} \url{http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm

U.S. Food and Drug Administration
Silver Spring, MD 20993
\url{www.fda.gov}
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOYCE A KORVICK
03/16/2020 05:26:48 PM